Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:58:23 2024-07-12 pm EDT			5-day change	1st Jan Change
1.75 ^USD	-28.04%		-21.17%	+101.15%

Jul. 03	Kiromic BioPharma, Inc. announced that it has received $2 million in funding	CI
Jun. 20	Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial	CI

Kiromic BioPharma, Inc. Announces Executive Changes

February 02, 2022 at 05:15 pm EST

Kiromic BioPharma, Inc. announced the appointment of Pietro Bersani as Interim Chief Executive Officer effective immediately. Mr. Bersani has served as a member of the company's Board since June 2020. Since April 2020, Mr. Bersani is a Partner with B2B CFO Partners, LLC.

The Board terminated Maurizio Chiriva-Internati as Chief Executive Officer for cause on January 27, 2022, after the Special Committee's Internal Review found evidence of conduct that the Board believed was inconsistent with the Company's policies.

Latest news about Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Jul. 02	CI
Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial	Jun. 20	CI
Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note	Jun. 07	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Jun. 02	CI
Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial	May. 29	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Apr. 30	CI
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	Apr. 24	CI
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	Apr. 02	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Apr. 01	CI
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	Mar. 19	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	Feb. 14	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Feb. 11	CI
Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer	Jan. 29	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Jan. 07	CI
Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial	Jan. 05	CI
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel? for the Treatment of Non-Small Cell Lung Cancer	Dec. 14	CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	Dec. 11	CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Kiromic Biopharma, Inc. Announces Deltacel?? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center	Nov. 09	CI
Kiromic BioPharma, Inc. and Beverly Hills Cancer Center Enter Clinical Trial Agreement	23-10-23	CI
Kiromic Biopharma, Inc. Appoints Brian Hungerford as Chief Financial Officer	23-10-03	CI
Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding	23-09-26	CI
Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from S&P TMI Index	23-09-18	CI

Chart Kiromic BioPharma, Inc.

Duration

Period

More charts

Company Profile

Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KIROMIC BIOPHARMA, INC.	+101.15%	2.71M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs